Wat is de prijs voor Novo Nordisk A/S (NOVO-B)

Het prijs van Novo Nordisk A/S (NOVO-B) is $41.14

Wat is de marktkapitalisatie voor Novo Nordisk A/S (NOVO-B)

Marktkapitalisatie voorNovo Nordisk A/S (NOVO-B) is $182.76B

Novo Nordisk A/S (NOVO-B) K/B-verhouding

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Jaar	P/B-ratio	Wijzigen
2026 (TTM)	5.61	-24.68%
2025	7.45	-61.56%
2024	19.38	-34.02%
2023	29.37	15.39%
2022	25.45	6.65%
2021	23.87	51.77%
2020	15.72	-1.35%
2019	15.94	12.22%
2018	14.20	-14.34%
2017	16.58	16.48%
2016	14.23	-34.97%
2015	21.89	29.23%
2014	16.94	35.36%
2013	12.51	-0.67%
2012	12.60	26.42%
2011	9.97	0.88%
2010	9.88	77.44%
2009	5.57	9.91%
2008	5.07	-20.41%
2007	6.36	25.26%
2006	5.08	20.40%
2005	4.22	11.39%
2004	3.79	16.59%
2003	3.25	4.96%
2002	3.10	-47.14%
2001	5.86	-4.54%
2000	6.14	0.00%

Jaar

P/B-ratio

Wijzigen

2026 (TTM)

5.61

-24.68%

2025

7.45

-61.56%

2024

19.38

-34.02%

2023

29.37

15.39%

2022

25.45

6.65%

2021

23.87

51.77%

2020

15.72

-1.35%

2019

15.94

12.22%

2018

14.20

-14.34%

2017

16.58

16.48%

2016

14.23

-34.97%

2015

21.89

29.23%

2014

16.94

35.36%

2013

12.51

-0.67%

2012

12.60

26.42%

2011

9.97

0.88%

2010

9.88

77.44%

2009

5.57

9.91%

2008

5.07

-20.41%

2007

6.36

25.26%

2006

5.08

20.40%

2005

4.22

11.39%

2004

3.79

16.59%

2003

3.25

4.96%

2002

3.10

-47.14%

2001

5.86

-4.54%

2000

6.14

0.00%

Bedrijf	P/B-ratio	Verschil in P/B-ratio	Land
Eli Lilly and Company LLY.US	29.9692	434.10%	US
Johnson & Johnson JNJ.US	7.6479	36.30%	US
AbbVie Inc. ABBV.US	-78.0908	-1,491.70%	US
Roche Holding AG RO.SW	8.4776	51.08%	CH
Merck & Co., Inc. MRK.US	8.5385	52.17%	US

Bedrijf

P/B-ratio

Verschil in P/B-ratio

Land